The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and ...

Symptoms and frequency of relapses vary widely from person to person with the most common form of multiple sclerosis — and doctors aren’t entirely sure why. But, what exactly does a relapse look like?

MS is due to the body’s defence system, or immune system, attacking the insulating cover of myelin that protects the nerves. This damages the nerves and impairs their ability to pass on electric ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

If your doctor says you have secondary progressive multiple sclerosis (SPMS), it means you're in a different stage of your disease. Most folks get it after living for a while with relapsing-remitting ...

The goal of this double-blind, adaptive, dose-ranging, phase 2 study was to assess safety, tolerability and dose-response characteristics of siponimod and its effects on brain MRI lesion activity in ...

Between relapses, people who have relapsing-remitting multiple sclerosis (RRMS) might not have any apparent symptoms or might even improve. Some feel well enough to go off medication. However, taking ...

There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal antibody, selectively targets and ...

Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis. July 2019: Fingolimod is contraindicated during pregnancy and in women of childbearing ...

Multiple sclerosis is a disorder of the immune system, where the myelin coating the nerve cells is damaged by antibodies formed by the defence system of the body. This affects the functioning of the ...